Rational Design and Organoid‐Based Evaluation of a Cocktail CAR‐γδ T Cell Therapy for Heterogeneous Glioblastoma
Advanced Science · 2025-05 · 12 (19)
DOI: 10.1002/advs.202501772 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 20.03.2025. Verfasst von Guidong Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250031, P.R. China. Hauptthemen laut MEDLINE: Glioblastoma, Immunotherapy, Adoptive, Organoids, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Program of Shandong Province, Shandong Province Postdoctoral Innovation Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Various challenges, including tumor heterogeneity and inadequate T cell infiltration, impede the progress of chimeric antigen receptor T cell (CAR‐T) therapy for glioblastoma (GBM). To address these obstacles, a multiple step strategy is designed. Initially, literature review and bioinformatics analysis to screen a set of antigens that are heterogeneously expressed in GBM, which are designated as the target‐bank, are leveraged. Then, according to the multiplex immunohistochemistry results of each patient's tumor sample, a personalized panel of antigens based on the principle that most cancer cells in tumor tissues can be covered from the target‐bank is selected. To target these antigens, Vδ1 T cells are chosen as CAR vehicles because of its high tissue infiltration and off‐the‐shelf properties, and an optimized protocol for engineering CAR‐Vδ1 T cells with high purity and cytotoxicity, low exhaustion, and cytokine release is developed. Next, the specific panel of cocktail CAR‐Vδ1 T cells in the GBM organoids that are directly derived from the same patient's tumor is tested. The term “ prof ” cocktail therapy is coined to describe the approach using precise and rational combination of tumor antigens, organoid‐based evaluation, and fitness of Vδ1 T cells. It may accelerate development of effective CAR‐T drugs for heterogeneous solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250031, P.R. China.
- Department of Neurosurgery, Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250031, P.R. China.
- Institute of Medical Sciences, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250031, P.R. China.
- Multidisciplinary Innovation Center for Nephrology of the Second Hospital of Shandong University, Jinan, 250031, China.
ORCID-Profile: Chengwei Wang
Förderung
- Key Research and Development Program of Shandong Province
- Shandong Province Postdoctoral Innovation Project
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Taishan Scholar Foundation of Shandong Province
- Key Technology Research and Development Program of Shandong Province
Zitieren
APA
Zhu, G., Sun, Z., Liu, Y., Liu, J., Guo, L., Pei, G., Jiang, Y., Miao, B., Li, Z., Zhang, P., Tang, D., Zhang, W., & Wang, C. (2025). Rational Design and Organoid‐Based Evaluation of a Cocktail CAR‐γδ T Cell Therapy for Heterogeneous Glioblastoma. Advanced Science, 12(19). https://doi.org/10.1002/advs.202501772
Vancouver
Zhu G, Sun Z, Liu Y, Liu J, Guo L, Pei G, et al. Rational Design and Organoid‐Based Evaluation of a Cocktail CAR‐γδ T Cell Therapy for Heterogeneous Glioblastoma. Advanced Science. 2025;12(19). doi:10.1002/advs.202501772
BibTeX
@article{Zhu2025,
author = {Zhu, Guidong and Sun, Zhongzheng and Liu, Yingchao and Liu, Jiang and Guo, Linpei and Pei, Guojing and Jiang, Ying and Miao, Baowang and Li, Zhen and Zhang, Ping and Tang, Dongqi and Zhang, Wen and Wang, Chengwei},
title = {Rational Design and Organoid‐Based Evaluation of a Cocktail CAR‐γδ T Cell Therapy for Heterogeneous Glioblastoma},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {19},
doi = {10.1002/advs.202501772}
}
EUVIMED